FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileKailera Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
KLRA
Kailera Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Kailera Therapeutics, Inc. (KLRA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisKLRA
KLRA
Kailera Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
KLRA
  1. Home
  2. Stocks
  3. Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc.

🇺🇸KLRA•NASDAQ

Kailera Therapeutics, Inc.

🇺🇸KLRA•NASDAQ
Market cap
$1.43B

Your view on KLRA

Mkt Cap
$1.43B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Kailera Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Ronald C. Renaud Jr.
Headquarters
180 Third Avenue, 4th Floor, Waltham, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Ronald C. Renaud Jr.
Headquarters
180 Third Avenue, 4th Floor, Waltham, MA, US
Description

Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders.

The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Kailera Therapeutics, Inc.. Starting points for Kailera Therapeutics, Inc.: EPS -$2.69, beta 0.50 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Kailera Therapeutics, Inc.. Trailing twelve-month EPS for Kailera Therapeutics, Inc. stands at -$2.69. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 21, 2026
Analysts' target$42.00average of analysts' targets
Current price—

Targets, low to high

$42.00

Low $36.00

Middle $42.00

High $48.00

More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.90−$0.84−$3.92−$3.86
Lowest estimate−$1.01−$0.84−$4.71−$4.55
Highest estimate−$0.80−$0.84−$3.13−$2.91
Number of analysts4145
A year ago—−$3,650.001−$1.261—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$0.00$0.00$0.00$0.00
Lowest estimate$0.00$0.00$0.00$0.00
Highest estimate$0.00$0.00$0.00$0.00
Number of analysts0000
A year ago—$0.00$0.00—
Growth vs a year ago————
Recent rating and target changes (2)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Kailera Therapeutics, Inc.. Kailera Therapeutics, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold KLRA20 companies · 8 funds
Compare KLRA with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ALTAltimmune, Inc.HealthcareBiotechnology$258.8M
BIOABioAge Labs, Inc.HealthcareBiotechnology$161.1M
BMEABiomea Fusion, Inc.HealthcareBiotechnology$41.7M
GUTSFractyl Health, Inc. Common StockHealthcareBiotechnology$10.9M
MBXMBX Biosciences, Inc. Common StockHealthcareBiotechnology$2.5B
MTVAMetaVia Inc.HealthcareBiotechnology$6.8M
NAMSNewAmsterdam Pharma Company N.V.HealthcareBiotechnology$2.2B
ORMPOramed Pharmaceuticals Inc.HealthcareBiotechnology$155.2M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
NXTCNextCure, Inc.HealthcareNASDAQ$29.5M
NYMXFNymox Pharmaceutical CorporationHealthcareOTC$4.8M
NYR.AXNyrada Inc.HealthcareASX—
OABIOmniAb, Inc.HealthcareNASDAQ$679.7M
OABIWOmniAb, Inc.HealthcareNASDAQ$733.7M
OBIOOrchestra BioMed Holdings, Inc.HealthcareNASDAQ$517.9M
MDXGMiMedx Group, Inc.HealthcareNASDAQ$445.1M
MEM.AXMemphasys LimitedHealthcareASX—
MENSJyong Biotech Ltd. Ordinary SharesHealthcareNASDAQ$110.2M
MEOBFMesoblast LimitedHealthcareOTC$2.1B
MESOMesoblast LimitedHealthcareNASDAQ$1.4B
MGNXMacroGenics, Inc.HealthcareNASDAQ$125.3M
ETFs holding Kailera Therapeutics, Inc.
TickerFundFund assets% of the fund
XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.15%
IWMiShares Russell 2000 ETF$76.6B in assets0.02%
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
VBVanguard Small-Cap ETF$76.9B in assets0.01%
OZEMRoundhill Investments - GLP-1 & Weight Loss ETF$57M in assets4.40%
SBIOALPS Medical Breakthroughs ETF$187M in assets1.02%
VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.03%
RSSLGlobal X - Russell 2000 ETF$1.4B in assets0.02%

Largest holders first, then the funds most concentrated in KLRA.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Kailera Therapeutics, Inc., and how their positions are changing. At a $1.43B market value, institutional positions materially move Kailera Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Kailera Therapeutics, Inc. executives and directors. Shares of Kailera Therapeutics, Inc. have traded between $16.39 and $28.23 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Kailera Therapeutics, Inc.. Coverage tracks Kailera Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Kailera Therapeutics, Inc.

KLRA AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1